Microneedle‐based intradermal delivery of stabilized dengue virus
Abstract Current live‐attenuated dengue vaccines require strict cold chain storage. Methods to preserve dengue virus (DENV) viability, which enable vaccines to be transported and administered at ambient temperatures, will be decisive towards the implementation of affordable global vaccination scheme...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Bioengineering & Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/btm2.10127 |
id |
doaj-84f70a242ef44a06a3d16b75ac6b2697 |
---|---|
record_format |
Article |
spelling |
doaj-84f70a242ef44a06a3d16b75ac6b26972020-11-25T01:05:14ZengWileyBioengineering & Translational Medicine2380-67612019-05-0142n/an/a10.1002/btm2.10127Microneedle‐based intradermal delivery of stabilized dengue virusMichelle E. Turvey0Divakara S.S.M. Uppu1Abdul Rahim Mohamed Sharif2Katell Bidet3Sylvie Alonso4Eng Eong Ooi5Paula T. Hammond6Infectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeInfectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeInfectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeInfectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeDepartment of Microbiology & Immunology, Yong Loo Lin School of Medicine, Immunology Programme Life Sciences Institute, National University of Singapore SingaporeInfectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeInfectious Diseases IRG Singapore‐MIT Alliance for Research and Technology SingaporeAbstract Current live‐attenuated dengue vaccines require strict cold chain storage. Methods to preserve dengue virus (DENV) viability, which enable vaccines to be transported and administered at ambient temperatures, will be decisive towards the implementation of affordable global vaccination schemes with broad immunization coverage in resource‐limited areas. We have developed a microneedle (MN)‐based vaccine platform for the stabilization and intradermal delivery of live DENV from minimally invasive skin patches. Dengue virus‐stabilized microneedle arrays (VSMN) were fabricated using saccharide‐based formulation of virus and could be stored dry at ambient temperature up to 3 weeks with maintained virus viability. Following intradermal vaccination, VSMN‐delivered DENV was shown to elicit strong neutralizing antibody responses and protection from viral challenge, comparable to that of the conventional liquid vaccine administered subcutaneously. This work supports the potential for MN‐based dengue vaccine technology and the progression towards cold chain‐independence. Dengue virus can be stabilized using saccharide‐based formulations and coated on microneedle array vaccine patches for storage in dry state with preserved viability at ambient temperature (VSMN; virus‐stabilized microneedle arrays).https://doi.org/10.1002/btm2.10127dengueimmunization cold chainmicroneedlesvaccine delivery |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michelle E. Turvey Divakara S.S.M. Uppu Abdul Rahim Mohamed Sharif Katell Bidet Sylvie Alonso Eng Eong Ooi Paula T. Hammond |
spellingShingle |
Michelle E. Turvey Divakara S.S.M. Uppu Abdul Rahim Mohamed Sharif Katell Bidet Sylvie Alonso Eng Eong Ooi Paula T. Hammond Microneedle‐based intradermal delivery of stabilized dengue virus Bioengineering & Translational Medicine dengue immunization cold chain microneedles vaccine delivery |
author_facet |
Michelle E. Turvey Divakara S.S.M. Uppu Abdul Rahim Mohamed Sharif Katell Bidet Sylvie Alonso Eng Eong Ooi Paula T. Hammond |
author_sort |
Michelle E. Turvey |
title |
Microneedle‐based intradermal delivery of stabilized dengue virus |
title_short |
Microneedle‐based intradermal delivery of stabilized dengue virus |
title_full |
Microneedle‐based intradermal delivery of stabilized dengue virus |
title_fullStr |
Microneedle‐based intradermal delivery of stabilized dengue virus |
title_full_unstemmed |
Microneedle‐based intradermal delivery of stabilized dengue virus |
title_sort |
microneedle‐based intradermal delivery of stabilized dengue virus |
publisher |
Wiley |
series |
Bioengineering & Translational Medicine |
issn |
2380-6761 |
publishDate |
2019-05-01 |
description |
Abstract Current live‐attenuated dengue vaccines require strict cold chain storage. Methods to preserve dengue virus (DENV) viability, which enable vaccines to be transported and administered at ambient temperatures, will be decisive towards the implementation of affordable global vaccination schemes with broad immunization coverage in resource‐limited areas. We have developed a microneedle (MN)‐based vaccine platform for the stabilization and intradermal delivery of live DENV from minimally invasive skin patches. Dengue virus‐stabilized microneedle arrays (VSMN) were fabricated using saccharide‐based formulation of virus and could be stored dry at ambient temperature up to 3 weeks with maintained virus viability. Following intradermal vaccination, VSMN‐delivered DENV was shown to elicit strong neutralizing antibody responses and protection from viral challenge, comparable to that of the conventional liquid vaccine administered subcutaneously. This work supports the potential for MN‐based dengue vaccine technology and the progression towards cold chain‐independence. Dengue virus can be stabilized using saccharide‐based formulations and coated on microneedle array vaccine patches for storage in dry state with preserved viability at ambient temperature (VSMN; virus‐stabilized microneedle arrays). |
topic |
dengue immunization cold chain microneedles vaccine delivery |
url |
https://doi.org/10.1002/btm2.10127 |
work_keys_str_mv |
AT michelleeturvey microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT divakarassmuppu microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT abdulrahimmohamedsharif microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT katellbidet microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT sylviealonso microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT engeongooi microneedlebasedintradermaldeliveryofstabilizeddenguevirus AT paulathammond microneedlebasedintradermaldeliveryofstabilizeddenguevirus |
_version_ |
1725195352580030464 |